Berberine Reduces Waist Size and Blood Sugar in Clinical Trial

Berberine has been accumulating research for its beneficial impact on metabolic syndrome, insulin sensitivity, and insulin secretion.

In this randomized, double-blind, placebo-controlled clinical trial on 24 patients with a diagnosis of metabolic syndrome, berberine was studied for its effect on waist size and other metabolic measures.  12 patients received 500 mg of berberine three times daily before meals for 3 months. The remaining 12 patients received a placebo.

By the end of the study, 36% of the patients no longer had metabolic syndrome and there was a significant decrease in waist circumference in females. There was also a reduction in systolic blood pressure, triglycerides, glucose, and insulin.

According to the authors of the study:

“Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity.”